Login / Signup

Dihydroorotate dehydrogenase inhibitor olorofim has potent in vitro activity against Microascus/Scopulariopsis, Rasamsonia, Penicillium and Talaromyces species.

Nathan P WiederholdHoja P PattersonCarmita J SandersConnie Cañete-Gibas
Published in: Mycoses (2022)
The investigational agent olorofim demonstrated good in vitro activity against clinical isolates of emerging mould pathogens, including those with reduced susceptibility or resistance to clinically available antifungals. Further studies are warranted to determine how well this in vitro activity translates into in vivo efficacy against infections caused by these fungi.
Keyphrases
  • randomized controlled trial
  • clinical trial
  • gram negative
  • anti inflammatory
  • open label